HC Wainwright Issues Positive Forecast for OLMA Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimate for Olema Pharmaceuticals from ($0.82) to ($0.43) per share, indicating improved expectations for the company's performance.
• Institutional investors hold a significant stake in Olema Pharmaceuticals, with 91.78% of the stock owned by them, reflecting strong institutional confidence in the company.
• Despite recently reporting a loss of ($0.51) per share for the last quarter, several brokerages have issued positive ratings, including JPMorgan raising their target price for the stock from $28.00 to $29.00.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Research analysts at HC Wainwright boosted their Q3 2025 earnings per share estimates for Olema Pharmaceuticals in a research note issued to investors on Tuesday, September 2nd. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.43) for the quarter, up from their previous estimate of ($0.82). The consensus estimate for Olema Pharmaceuticals' current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals' Q4 2025 earnings at ($0.51) EPS and FY2026 earnings at ($2.30) EPS.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.08).

OLMA has been the subject of several other research reports. The Goldman Sachs Group lowered their price target on Olema Pharmaceuticals from $20.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. JPMorgan Chase & Co. increased their target price on Olema Pharmaceuticals from $28.00 to $29.00 and gave the stock an "overweight" rating in a research report on Thursday, August 14th. Citigroup increased their target price on Olema Pharmaceuticals from $20.00 to $21.00 and gave the stock a "buy" rating in a research report on Tuesday, August 12th. Oppenheimer reaffirmed an "outperform" rating and issued a $22.00 target price on shares of Olema Pharmaceuticals in a research report on Wednesday, September 3rd. Finally, Zacks Research raised Olema Pharmaceuticals to a "strong sell" rating in a research report on Monday, August 11th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $24.00.

Olema Pharmaceuticals Trading Up 5.3%

OLMA traded up $0.40 during midday trading on Friday, hitting $7.84. The company's stock had a trading volume of 660,355 shares, compared to its average volume of 891,668. The company has a current ratio of 11.09, a quick ratio of 11.09 and a debt-to-equity ratio of 0.01. The firm has a market cap of $537.75 million, a P/E ratio of -3.96 and a beta of 1.92. The firm has a 50-day moving average price of $5.26 and a two-hundred day moving average price of $4.70. Olema Pharmaceuticals has a 52-week low of $2.86 and a 52-week high of $13.93.

Hedge Funds Weigh In On Olema Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Thrivent Financial for Lutherans acquired a new position in Olema Pharmaceuticals during the 2nd quarter worth approximately $308,000. Bridgeway Capital Management LLC acquired a new position in Olema Pharmaceuticals during the 2nd quarter worth approximately $213,000. Birchview Capital LP acquired a new position in Olema Pharmaceuticals during the 2nd quarter worth approximately $571,000. Ameriprise Financial Inc. lifted its position in Olema Pharmaceuticals by 193.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,172,863 shares of the company's stock worth $4,996,000 after acquiring an additional 773,064 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Olema Pharmaceuticals by 46.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,442 shares of the company's stock worth $96,000 after acquiring an additional 7,146 shares in the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.